3.1 Clinical Assessment, Infection Screening, and Severity Stratification

Structured Clinical Assessment and Infectious Disease History

A meticulous, structured clinical evaluation is the cornerstone of infectious diseases pharmacotherapy. Board-certified infectious diseases specialists must synthesize subtle historical cues with physiologic derangements to formulate tailored differential diagnoses and antimicrobial regimens.

Core Elements of the Infectious Disease History

1. Timeline and Progression of Symptoms:

   • Establishing the exact onset, velocity, and trajectory of symptoms differentiates acute fulminant processes (such as meningococcal meningitis or necrotizing fasciitis) from subacute or indolent infections (such as infective endocarditis, tuberculosis, or fungal osteomyelitis).
   • Clinicians should elicit constitutional signs: subjective rigors (strongly associated with true bacteremia), drenching night sweats, involuntary weight loss, localized focal pain, new-onset cough, sputum production, and altered mentation.

2. Antimicrobial Exposure Within the Preceding 90 Days:

   • Prior antimicrobial pressure is the single strongest predictor of multidrug-resistant organism (MDRO) infection. Exposure within 90 days exerts profound ecological pressure, selecting for methicillin-resistant Staphylococcus aureus (MRSA), extended-spectrum beta-lactamase (ESBL)-producing Enterobacterales, AmpC beta-lactamase producers, carbapenem-resistant Enterobacterales (CRE), multidrug-resistant Pseudomonas aeruginosa, Stenotrophomonas maltophilia, and Clostridioides difficile.
   • Documenting the specific agent, dose, duration, and patient adherence is essential.

3. Epidemiologic Exposures (Travel, Vectors, and Occupation):

   • Geographic and Travel History: Residence or travel within endemic geographic niches suggests specific pathogens: the Southwestern United States and Sonoran Desert for Coccidioides; the Ohio and Mississippi River Valleys, caves, or bird/bat roosts for Histoplasma; the Upper Midwest, Great Lakes, and river basins for Blastomyces; international travel for malaria (Plasmodium spp.), dengue, chikungunya, or Salmonella enterica serovar Typhi.
   • Animal and Vector Exposures: Tick bites or wooded exposures in the Northeast and Upper Midwest suggest Lyme disease (Borrelia burgdorferi), babesiosis (Babesia microti), and anaplasmosis (Anaplasma phagocytophilum). Dog and cat bites or scratches introduce Pasteurella multocida, Bartonella henselae (cat scratch disease), or Capnocytophaga canimorsus (fulminant sepsis in asplenic patients). Farm or livestock contact raises concern for Brucella, Coxiella burnetii (Q fever), or Bacillus anthracis.
   • Occupational and Recreational Risks: Healthcare workers (bloodborne pathogens, resistant nosocomial isolates); wastewater and sanitation workers (Leptospira interrogans); spelunkers (Histoplasma capsulatum); gardeners and landscapers (Sporothrix schenckii); fish and poultry handlers (Erysipelothrix rhusiopathiae, Mycobacterium marinum).

4. Sexual and Substance Use History:

   • Detailed anatomical site history (urogenital, pharyngeal, anorectal) guides targeted screening for Neisseria gonorrhoeae, Chlamydia trachomatis, Treponema pallidum, and mpox.
   • Injection drug use history dictates high suspicion for native right- or left-sided valve infective endocarditis, septic pulmonary emboli, spinal epidural abscess, vertebral osteomyelitis, and bloodstream infections caused by S. aureus, Streptococcus spp., Candida spp., and Pseudomonas.

5. Prior Microbiological and Colonization Records:

   • Reviewing historical culture results and colonization surveillance (e.g., prior nasal MRSA swabs, rectal CRE swabs, or vancomycin-resistant Enterococcus [VRE] screens) substantially refines empiric therapy.

---

Physical Examination and Bedside Severity Stratification

Bedside evaluation must capture acute vital sign abnormalities and overt signs of microvascular failure.

Vital Sign Derangements and Hypoperfusion Indicators

• Temperature Derangements: Core temperature >38.0°C (100.4°F) signals systemic cytokine activation, but hypothermia (<36.0°C or 96.8°F) represents an ominous clinical sign indicating severe immune exhaustion or distributive collapse, frequently encountered in elderly, cirrhotic, or uremic patients in septic shock.
• Tachypnea: Respiratory rate >20 to 22 breaths/min is often the earliest and most sensitive bedside predictor of metabolic acidosis (compensatory respiratory alkalosis) and evolving systemic sepsis.
• Microvascular Perfusion Derangements:
  • Prolonged Capillary Refill Time (CRT): Peripheral CRT >3 seconds (measured on the ventral distal index finger or patella) reflects severe peripheral vasoconstriction and occult shock. The landmark ANDROMEDA-SHOCK trial demonstrated that CRT-targeted resuscitation was associated with improved organ dysfunction and lower mortality compared to protocolized lactate normalization.
  • Cutaneous Mottling Score: A validated 0-to-5 bedside clinical scale grading livedo reticularis extension over the patella and thigh (0 = no mottling; 1 = coin-sized patellar patch; 2 = mottling covering patella; 3 = extending to mid-thigh; 4 = extending to groin; 5 = extending beyond groin). Scores >=2 to 3 strongly predict 14-day mortality in septic shock.
  • Oliguria: Urine output <0.5 mL/kg/h for >=2 consecutive hours despite adequate fluid resuscitation denotes renal hypoperfusion and impending acute tubular necrosis.
  • Altered Mental Status: Acute encephalopathy, confusion, or agitation reflects impaired cerebral microvascular autoregulation and neuroinflammation.

Bedside Severity Scoring Systems

Understanding the distinction between inflammatory screening tools and validated organ dysfunction scores is essential for clinical practice and specialty examinations.

---

Diagnostic Screening: Nasal MRSA PCR and Antimicrobial Stewardship

Rapid real-time polymerase chain reaction (PCR) screening for MRSA nares colonization represents one of the highest-impact diagnostic stewardship tools in hospital practice.

Assay Mechanism and Operating Characteristics

Nasal MRSA PCR identifies the junction between the staphylococcal cassette chromosome mec (SCCmec) element carrying the mecA or mecC methicillin-resistance genes and the Staphylococcus aureus chromosomal orfX gene. This design differentiates true MRSA from methicillin-resistant coagulase-negative staphylococci (MRCoNS) or methicillin-susceptible S. aureus (MSSA).

• Diagnostic Accuracy in Lower Respiratory Tract Infections (Pneumonia):
  • Negative Predictive Value (NPV): 95% to 99.2% across community-acquired pneumonia (CAP), hospital-acquired pneumonia (HAP), and ventilator-associated pneumonia (VAP).
  • Positive Predictive Value (PPV): Modest (30% to 50%), reflecting frequent asymptomatic nares carriage without invasive parenchymal lung infection.

Clinical Stewardship Implications in Pneumonia

Because S. aureus pneumonia requires prior upper airway colonization in over 95% of cases, a negative MRSA nasal PCR reliably excludes MRSA as the causative pulmonary pathogen. IDSA/ATS pneumonia guidelines support using a negative nasal PCR to discontinue empiric vancomycin, linezolid, or ceftaroline within 24 to 48 hours of admission.

Benefits of prompt de-escalation based on a negative nasal PCR:

• Prevention of vancomycin-associated acute kidney injury (nephrotoxicity incidence 10% to 20%).
• Elimination of invasive therapeutic drug monitoring (trough or AUC-guided phlebotomy).
• Reduced selective pressure for vancomycin-resistant enterococci (VRE) and daptomycin-non-susceptible organisms.
• Shortened hospital length of stay and significant pharmacy cost containment.

Critical Clinical Limitation: Skin and Soft Tissue Infections (SSTI)

In purulent skin and soft tissue infections, diabetic foot infections, and surgical site infections, the correlation between nasal colonization and the infective pathogen is markedly lower. The negative predictive value of a nasal MRSA swab in SSTI drops to 75% to 85%. Therefore, a negative nasal MRSA PCR cannot be used as a standalone justification to withhold or discontinue empiric anti-MRSA coverage in severe purulent cellulitis, necrotizing soft tissue infection, or complicated surgical wound infections.

---

Disease-Specific Clinical Severity Assessment Tools

Validated prognostic scores stratify infection severity, guide site-of-care decisions (outpatient vs. inpatient ward vs. intensive care unit), and standardize therapeutic escalation.

1. Community-Acquired Pneumonia: CURB-65 vs. PSI (PORT Score)

• CURB-65 Score: Assigns 1 point for each of 5 variables:
  • C: Confusion (abbreviated mental test score <=8 or new disorientation)
  • U: Blood urea nitrogen (BUN) >19 mg/dL (>7 mmol/L)
  • R: Respiratory rate >=30 breaths/min
  • B: Blood pressure (Systolic BP <90 mmHg or Diastolic BP <=60 mmHg)
  • 65: Age >=65 years
  • Risk Tiers and Disposition: Score 0 to 1 = low mortality (<1.5%), eligible for outpatient management; Score 2 = moderate mortality (8% to 9%), inpatient floor admission or closely monitored outpatient care; Score 3 to 5 = high mortality (15% to 40%), mandatory hospital admission, with scores 4 to 5 prompting intensive care unit consideration.
• Pneumonia Severity Index (PSI / PORT): Incorporates 20 demographic, comorbid, physical, and laboratory variables into a point calculation that assigns patients to Risk Classes I through V. Classes I to II are managed as outpatients; Class III may be managed in an observation unit or short inpatient stay; Classes IV and V mandate inpatient admission with high ICU utilization. PSI is more sensitive than CURB-65 in identifying low-risk candidates for outpatient care.

2. Clostridioides difficile Infection (IDSA/SHEA Severity Staging)

3. Pitt Bacteremia Score

A validated bedside acute physiology score (range 0 to 14 points) utilized in bloodstream infection research and clinical stewardship:

• Measures 5 clinical domains: oral temperature (points for fever or hypothermia), systolic blood pressure (points for hypotension requiring vasopressors), mechanical ventilation, cardiac arrest, and mental status (alert, disoriented, stuporous, or comatose).
• A Pitt Bacteremia Score >=4 denotes critical illness with substantially elevated 14-day and 30-day mortality, alerting the stewardship pharmacist to prioritize aggressive regimen optimization, combination therapy where indicated, and source control.

4. MASCC Risk Index for Febrile Neutropenia

The Multinational Association for Supportive Care in Cancer (MASCC) score identifies cancer patients with febrile neutropenia at low risk for medical complications:

• Evaluates symptom severity (no or mild symptoms = 5 points; moderate symptoms = 3 points), absence of hypotension (5 points), absence of chronic obstructive pulmonary disease (4 points), solid tumor or hematologic malignancy without prior fungal infection (4 points), outpatient status at fever onset (3 points), absence of dehydration (3 points), and age <60 years (2 points). Maximum score = 26 points.
• Score >=21: Defines low-risk febrile neutropenia (<5% risk of severe medical complications). These patients are candidates for outpatient oral antimicrobial therapy with ciprofloxacin 750 mg PO BID plus amoxicillin-clavulanate 875/125 mg PO BID (or oral levofloxacin 750 mg daily monotherapy in penicillin-allergic patients).
• Score <21: Defines high-risk febrile neutropenia, mandating immediate hospitalization and broad-spectrum antipseudomonal intravenous monotherapy (cefepime, meropenem, or piperacillin-tazobactam).

---

Asymptomatic Bacteriuria (ASB) vs. Symptomatic Urinary Tract Infection

Overtreatment of asymptomatic bacteriuria is one of the most pervasive antimicrobial stewardship challenges worldwide, driving adverse drug reactions, C. difficile colitis, and antimicrobial resistance.

Defining Asymptomatic Bacteriuria

Asymptomatic bacteriuria is defined as the isolation of a specified quantitative count of bacteria in a properly collected clean-catch voided urine specimen (>=10^5 CFU/mL of a single organism in two consecutive specimens in women or a single specimen in men, or >=10^2 CFU/mL in a catheterized specimen) in an individual without local urinary tract symptoms (dysuria, frequency, urgency, gross hematuria, suprapubic pain, or costovertebral angle tenderness) or systemic signs attributable to a urinary source.

Mandatory Indications to Screen and Treat ASB

Under IDSA guidelines, there are only two clinical scenarios where screening and treating ASB is proven to improve patient outcomes:

1. Pregnant Individuals:

   • Rationale: Anatomic and hormonal changes (ureteral dilation, reduced bladder tone, progesterone-mediated urinary stasis) allow untreated ASB to progress to acute pyelonephritis in 20% to 30% of cases, predisposing to preterm labor, low birth weight, and perinatal mortality.
   • Management: Screen all pregnant individuals via clean-catch urine culture at 12 to 16 weeks gestation (or at the first prenatal visit). If positive, treat with 4 to 7 days of pregnancy-safe oral antimicrobials (e.g., cephalexin, nitrofurantoin [avoid during first trimester and near term/delivery], fosfomycin tromethamine, or amoxicillin-clavulanate). Obtain a periodic test-of-cure culture following treatment.

2. Patients Undergoing Urologic Procedures with Anticipated Mucosal Bleeding:

   • Rationale: Transurethral resection of the prostate (TURP), ureteroscopy with lithotripsy, or other mucosal-disrupting endourologic procedures can translocate colonized bacteria directly into disrupted pelvic veins, causing bacteremia and septic shock in up to 60% of untreated patients.
   • Management: Screen via urine culture prior to surgery. Administer targeted antimicrobial therapy initiated 30 to 60 minutes before the procedure and discontinue immediately post-procedure unless an indwelling catheter remains.

Populations Where Screening and Treatment of ASB is Strictly Contraindicated

In the following patient populations, IDSA guidelines explicitly recommend AGAINST screening or treating asymptomatic bacteriuria:

• Chronically Catheterized Patients (CA-ASB): Bacteriuria and pyuria are ubiquitous within 3 to 4 days of catheterization. Treating CA-ASB does not prevent symptomatic catheter-associated UTI (CAUTI) or bacteremia, but rapidly selects for resistant pathogens (e.g., carbapenem-resistant Pseudomonas, Enterococcus).
• Older Institutionalized or Community-Dwelling Adults: ASB prevalence exceeds 25% to 50% in institutionalized women and 15% to 40% in institutionalized men. Pyuria is present in >90% of colonized elderly individuals. Antimicrobial therapy does not reduce symptomatic UTI episodes or mortality, but increases adverse drug events and C. difficile rates.
• Patients with Diabetes Mellitus: Even with poor glycemic control, treating ASB does not prevent nephropathy, symptomatic UTI, or hospitalizations.
• Patients with Spinal Cord Injury or Neurogenic Bladder: Chronic colonization is normal; antimicrobial exposure fosters resistant uropathogens.
• Patients Prior to Non-Urologic Elective Surgeries: Screening and treating ASB prior to total hip or knee arthroplasty, cardiovascular procedures, or spine surgery does not decrease surgical site infections and is strongly discouraged.
• Renal Transplant Recipients >3 Months Post-Transplantation: Absent specific anatomical complications, treating asymptomatic bacteriuria after the initial 3-month post-engraftment period does not improve graft survival or prevent pyelonephritis.